Juvenile Idiopathic Arthritis
164
21
23
91
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
25 trials with published results (15%)
Research Maturity
91 completed trials (55% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.7%
6 terminated out of 164 trials
93.8%
+7.3% vs benchmark
23%
38 trials in Phase 3/4
27%
25 of 91 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 91 completed trials
Clinical Trials (164)
Feasibility of a Diet Intervention for Juvenile Arthritis
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis
Host-microbiota-environment Interactions
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
Treatment Tapering in JIA With Inactive Disease
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Transition to Adulthood Through Coaching and Empowerment
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Biomarkers in Pediatric Inflammatory Rheumatic Diseases
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
Dynamic Gait Index as a Functional Gait Assessment Measure in Children With JIA
Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis